Merck Announces Second-Quarter 2024 Financial Results

Details

GAAP earnings per share (EPS) was $2.14, and non-GAAP EPS was $2.28. Key highlights include a 16% growth in KEYTRUDA sales to $7.3 billion and the successful initial launch of WINREVAIR in the U.S. The company also achieved key milestones in its vaccine programs, including the FDA approval of CAPVAXIVE and positive results from a Phase 2b/3 trial of an RSV preventative monoclonal antibody. Merck completed acquisitions of EyeBio and Elanco's aqua business in July 2024 and raised its full-year financial outlook.

Items reported

Exhibits (2)

About Merck & Co., Inc.

Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.